Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
Werutsky G, Maluf FC, Cronemberger EH, Carrera Souza V, Dos Santos Martins SP, Peixoto F, Smaletz O, Schutz F, Herchenhorn D, Santos T, Mavignier Carcano F, Queiroz Muniz D, Nunes Filho PRS, Zaffaroni F, Barrios C, Fay A. Werutsky G, et al. Among authors: herchenhorn d. BMC Cancer. 2019 May 23;19(1):487. doi: 10.1186/s12885-019-5709-y. BMC Cancer. 2019. PMID: 31122212 Free PMC article. Clinical Trial.
XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy.
Pinho MB, Costas F, Sellos J, Dienstmann R, Andrade PB, Herchenhorn D, Peixoto FA, Santos VO, Small IA, Guimarães DP, Ferreira CG. Pinho MB, et al. Among authors: herchenhorn d. Urol Oncol. 2009 Jul-Aug;27(4):382-90. doi: 10.1016/j.urolonc.2008.03.016. Epub 2008 Jun 16. Urol Oncol. 2009. PMID: 18555708 Clinical Trial.
Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer.
Nogueira-Rodrigues A, do Carmo CC, Viegas C, Erlich F, Camisão C, Fontão K, Lima R, Herchenhorn D, Martins RG, Moralez GM, Small IA, Ferreira CG. Nogueira-Rodrigues A, et al. Among authors: herchenhorn d. Clin Cancer Res. 2008 Oct 1;14(19):6324-9. doi: 10.1158/1078-0432.CCR-07-5112. Clin Cancer Res. 2008. PMID: 18829516 Clinical Trial.
Castration-resistant prostate cancer: systemic therapy in 2012.
Maluf FC, Smaletz O, Herchenhorn D. Maluf FC, et al. Among authors: herchenhorn d. Clinics (Sao Paulo). 2012;67(4):389-94. doi: 10.6061/clinics/2012(04)13. Clinics (Sao Paulo). 2012. PMID: 22522765 Free PMC article. Review.
First Brazilian Consensus of Advanced Prostate Cancer: Recommendations for Clinical Practice.
Sasse AD, Wiermann EG, Herchenhorn D, Bastos DA, Schutz FA, Maluf FC, Coura G Filho, Morbeck IAP, Cerci JJ, Smaletz O, Lima VS, Adamy A Jr, Campos FS, Carvalhal GF, Cezar LC, Dall'Oglio MF, Sadi MV, Reis RBD, Nogueira L. Sasse AD, et al. Among authors: herchenhorn d. Int Braz J Urol. 2017 May-Jun;43(3):407-415. doi: 10.1590/S1677-5538.IBJU.2016.0490. Int Braz J Urol. 2017. PMID: 28199075 Free PMC article.
Second brazilian consensus on the treatment of advanced prostate cancer - a SBOC-SBU-SBRT panel review.
Sasse AD, Dos Reis RB, Nogueira LM, Maluf FC, Herchenhorn D, Smaletz O, Lima VS, Schutz F, Bastos D, Wiermann EG, Morbeck IAP, Jardim LF, Souza VC, Carvalho IT, Leite ETT, Nardozza A Jr, Pompeo ACL, Bretas F, Leal MLO, Sadi MV, da Ponte JRT, Carvalhal GF. Sasse AD, et al. Among authors: herchenhorn d. Int Braz J Urol. 2019 May-Jun;45(3):449-458. doi: 10.1590/S1677-5538.IBJU.2018.0798. Int Braz J Urol. 2019. PMID: 31038861 Free PMC article.
42 results